Get started
Author

SM Ali

Institutions: BC Cancer Agency, Pennsylvania State University, Queen's University, Lebanon VA Medical Center, ProteinSimple (United States), Canadian Cancer Trials Group, Penn State Milton S. Hershey Medical Center
Observed institutions: Poznan University of Medical Sciences, BC Cancer Agency, Houston Methodist, Pennsylvania State University, Beth Israel Deaconess Medical Center, Sunnybrook Health Science Centre, Mayo Clinic, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Washington University in St. Louis, Queen's University, Avera Health, Johns Hopkins Medicine, Hadassah Medical Center, Jewish General Hospital, Massachusetts General Hospital, Lebanon VA Medical Center, Acceleron Pharma (United States), Greater Poland Cancer Center, Dana-Farber Cancer Institute, Novartis (United States), ProteinSimple (United States), Lublin Oncology Center, Mayo Clinic in Florida, Hospital de Santa Maria, R&D Systems (United States), Institute for Myeloma & Bone Cancer Research, Southeastern Health, Sidney Kimmel Comprehensive Cancer Center, Celgene (United States), Mayo Clinic Comprehensive Cancer Center (Florida), Rutgers Cancer Institute, Foundation Medicine (United States), Albany Medical College, Canadian Cancer Trials Group, McGill University, Gdańsk Medical University, Medical University of Vienna, Penn State Milton S. Hershey Medical Center
OpenAlex ID: A5103676690
Abstract P2-09-15: NTRK fusions in breast cancer: Clinical, pathologic and genomic findings
2018 · JS Ross, J Chung, et al. · Cancer Research · 21
Abstract P6-03-02: EGFR genomic alterations in 5,605 cases of refractory and metastatic breast cancer
2016 · SM Ali, K Wang, et al. · Cancer Research · 3
Abstract PD3-10: Higher serum PD-L1 predicts for increased overall survival to lapatinib vs trastuzumab in the phase 3 CCTG MA.31 trial
2019 · PR Moku, LE Shepherd, et al. · Cancer Research · 1
Abstract P6-03-12: Comprehensive genomic profiling of clinically advanced mucinous carcinoma of the breast
2016 · K Wang, SM Ali, et al. · Cancer Research · 1
Abstract P3-07-05: Non-amplification ERBB2 genomic alterations in 5,605 cases of refractory and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies
2016 · JS Ross, K Wang, et al. · Cancer Research · 1
HER2 protein expression predicts response to trastuzumab in FISH-positive patients.
2009 · A Lipton, SM Ali, et al. · Cancer Research · 1
Abstract P1-07-09: Serum activin A and outcomes in HR+ /HER2- metastatic breast cancer patients treated with everolimus: Results from BOLERO-2
2018 · SM Ali, D Chen, et al. · Cancer Research
Abstract PD8-01: CDH1 mutated classic and pleomorphic invasive lobular breast carcinomas differ in genomic signatures and opportunities for targeted and immunotherapies
2018 · JS Ross, J Chung, et al. · Cancer Research
Abstract P2-12-01: Comprehensive genomic profiling of 34 cases of breast angiosarcoma
2017 · V Ravi, R Madison, et al. · Cancer Research
Abstract P1-02-10: Reduced serum B-cell maturation antigen levels predict poor outcome in metastatic breast cancer patients in a phase 3 randomized 2nd-line hormone therapy trial
2017 · SM Ali, K Leitzel, et al. · Cancer Research
Abstract P3-07-02: Are we missing actionable targets in breast cancer? Novel insights into recurrent Ret alterations
2017 · KM Hirshfield, BS Paratala, et al. · Cancer Research
Abstract PD6-08: IMAGE: Individualized molecular analyses guide efforts in breast cancer with comprehensive genomic profiling of tissue and plasma tumor DNA
2016 · HA Parsons, JA Beaver, et al. · Cancer Research
Abstract A32: MCL1 gene amplification in breast cancer is associated with TNBC status and can respond to a sorafenib/vorinostat regimen
2016 · JS Ross, K Wang, et al. · Molecular Cancer Research
A Study on Histomorphological Spectrum of Childhood Malignant Tumour: Evaluation of 60 Cases at Different Center in Dhaka City
2014 · MI Karim, SM Ali, et al. · Journal of Armed Forces Medical College Bangladesh
PDF
Abstract P3-06-33: Effect of trastuzumab-based therapy on serum activin A levels in metastatic breast cancer.
2012 · LM Zubritsky, SM Ali, et al. · Cancer Research
Abstract P2-10-31: Correlation of quantitative p95HER2 and total HER2 levels with clinical outcomes in a combined analysis of two cohorts of trastuzumab-treated metastatic breast cancer patients
2012 · R Duchnowska, J Sperinde, et al. · Cancer Research
Abstract P2-09-07: Elevated Pretreatment Serum CA9 (CAIX) (Carbonic Anhydrase 9) Predicts Reduced Progression-Free and Overall Survival in Trastuzumab-Treated Metastatic Breast Cancer
2010 · UI Anyanwu, HY Hou, et al. · Cancer Research
Abstract P4-09-09: Serum SDF-1: Biomarker of Bone Relapse in the NCIC MA.14 Adjuvant Breast Cancer Trial
2010 · SM Ali, A Aguilar-Mahecha, et al. · Cancer Research
Works count: 18
Citation count: 28
H-index: 2
I10-index: 1
Year
Topic
Type